Altria Group MO

Reference table

1. What the business is, and a revenue line reported two ways

Altria describes itself as a tobacco holding company operating exclusively in the United States. Chief executive Salvatore Mancuso since 14 May 2026; approximately 5,900 employees — the smallest workforce in this batch against $20 billion of revenue; Richmond, Virginia.

Revenue by segment (seg_prod), which is on the NET REVENUES basis:

Two things follow. First, seg_prod is on the gross NET REVENUES basis and inc_a is on the REVENUES NET OF EXCISE TAXES basis — the two blocks in the same file use different lines of the same income statement, and they differ by about $3.2 billion of excise tax. No reconciliation is supplied. Second, the trend is unambiguous: Smokeable Products net revenues have fallen from $22,476M to $20,485M over four years, an 8.9% decline, while Smokeless has grown from $2,580M to $2,802M, up 8.6% over the same four years — but only 0.9% in the most recent year, which is the point.

seg_geo is EMPTY, and this is correct — Altria operates only in the United States. This is the same legitimate case as Progressive in this batch and it is recorded as legitimate rather than flagged as a defect.

2. The basis defect, and what the filing actually says

From the 10-Q filed 2026-07-30, the income statement:

And what inc_q shows:

The 2026 quarters are on the gross basis and the 2025 quarters are on the net-of-excise basis. A reader computing year-on-year growth from inc_q gets +15.5% for the June quarter and +20.1% for the March quarter. The true figures are +0.1% and, for the half, +1.6% on the same gross basis. This is the APP failure mode — two reporting bases inside one quarterly series making the growth rate unrecognisable — and it is the single most consequential data finding on this name.

A second, unrelated error compounds it. earn_cal.revenueActual reads $5,356M for BOTH the 2026-04-30 and the 2026-07-30 rows — an identical value in consecutive quarters — and matches neither the gross ($6,111M and $5,428M) nor the net-of-excise ($5,392M and $4,758M) figures. Against a Q1 estimate of $4,577.5M it manufactures a 17.0% revenue "beat" that did not happen. earn_cal revenue for Altria is discarded entirely; its EPS rows are used, having a consistent adjusted basis.

What the company actually discloses about its business

The 10-Q's own operating commentary is unusually direct and is quoted at length because it is the whole thesis:

> "Overall discretionary income pressures on adult nicotine consumers have resulted in increased discount brand share and contributed to evolving adult nicotine consumer preferences, each of which has negatively impacted the sales volumes of certain of our operating companies' premium brands. For the second quarter of 2026, the discount retail share of the cigarette category reached 33.8%, an increase of 2.6 share points versus the second quarter of 2025 and 0.5 share points sequentially. When adjusted for trade inventory movements, our smokeable products segment domestic cigarette shipment volume declined by an estimated 4.5% in the second quarter of 2026 versus the second quarter of 2025. When adjusted for trade inventory movements, total estimated domestic cigarette industry volume declined by 5% ... We believe moderating estimated domestic cigarette industry volume decline, which began in the third quarter of 2025, continues to primarily be driven by reduced cross-category movement between cigarettes and illicit flavored disposable e-vapor products. ... The U.S. nicotine pouch category continued to grow throughout the second quarter of 2026 to 59.9% of the U.S. oral tobacco category, an increase of 8.1 share points versus the second quarter of 2025 and 1.8 share points sequentially. As innovative smoke-free products evolve ... these consumers continue to transition from cigarettes and MST products to innovative smoke-free products, which has reduced the sales volumes of our operating companies' cigarette and MST products."

Four facts and each cuts a different way.

First, volume fell 4.5% and Altria outperformed the industry's 5%. Modest share gain in a shrinking pool.

Second, the discount share rose 2.6 points to 33.8%. This is the most important sentence in the filing. Altria's model is annual price increases on a premium brand. When a third of the category has moved to discount and that share is rising 2.6 points a year, the price lever is meeting the consumer's budget. The company attributes it explicitly to "discretionary income pressures."

Third, the industry decline is "moderating" — but for a reason that is not demand. The 10-Q says it is "primarily ... driven by reduced cross-category movement between cigarettes and illicit flavored disposable e-vapor products" — i.e., enforcement against illegal vapes is pushing users back to cigarettes. That is a regulatory tailwind, not a consumer one, and it can reverse.

Fourth, nicotine pouches took 8.1 share points of the oral category in twelve months, to 59.9%. Altria's Smokeless Products revenue grew 0.9% over the same period. The category is growing rapidly and Altria's moist-smokeless franchise is being displaced. A knowledge-base claim at conviction 70 puts the competitive reality plainly: modern-oral brands, once established, are very hard to displace — and the established one is not Altria's.

3. Margins, cash and the dividend

Revenue net of excise has FALLEN in each of the last four years, from $21,111M to $20,139M — a 4.6% cumulative decline. Operating margin has expanded from 52.2% to 59.8% over six years, which is how the earnings have been held up.

The fiscal 2024 net income of $11,264M and EPS of $6.54 are anomalous and should not be used as a base. Pre-tax income that year was $13,658M against $9,389M in fiscal 2025, and cf_a shows acquisitionsNet of +$2,353M — a large disposal gain (the fiscal 2024 EBITDA of $15,068M against fiscal 2025's $10,832M confirms it). Any growth rate computed off fiscal 2024 GAAP earnings is meaningless.

Free cash flow is the number that matters and it is exceptional. $9,074 million on $20,139 million of revenue — a 45.1% free-cash-flow margin — with capital expenditure of $216 million, which is 1.1% of revenue and the lowest in this batch by a wide margin. At the current market capitalisation that is a 7.98% free-cash-flow yield.

The dividend, and it is covered. $4.24 per share, a 6.23% yield. Fiscal 2025 dividends of $6,960 million against free cash flow of $9,074 million — 76.7% coverage. dividendPayoutRatioTTM of 85.6% is computed on GAAP earnings and is the less useful measure, because GAAP earnings are depressed by non-cash amortisation and by the absence of the fiscal 2024 disposal gain. On cash, the dividend has $2.1 billion of annual headroom. This is the direct contrast with Starbucks in this same batch, where the dividend EXCEEDED free cash flow by $329 million.

The buyback fell from $3,400 million in fiscal 2024 to $1,000 million in fiscal 2025 — a reduction that, combined with the dividend, means total capital returned fell from $10,245M to $7,960M. Diluted shares fell from 1,859M (FY2020) to 1,677M (FY2025) — a 9.8% reduction over five years, roughly 2% a year.

Negative shareholders' equity of $3,502 million requires the standard explanation and it is benign here. Retained earnings are PLUS $35,452 million — Altria has not lost money; it has returned more than it earned through buybacks and treasury stock over decades. priceToBookRatioTTM of −42.7x, debtToEquityRatioTTM of −9.21x and returnOnEquityTTM (null in ratios_ttm) are all meaningless and are rejected. returnOnInvestedCapitalTTM of 36.7% is the honest measure and it is the second highest in this batch.

Leverage is moderate: net debt of $22.2 billion at 1.89x EBITDA with 10.3x interest coverage, against $17,663 million of goodwill and intangibles on $35,017 million of assets.

4. Valuation — priced in or room?

At $68.07 (market cap $113.66B, ~1,669.6M shares, enterprise value $135.87B):

Estimate coverage is thin throughout and collapses after FY2027: 7-8 analysts on FY2026 and FY2027, only 3 on FY2028 EPS, and ONE on each of FY2029 and FY2030. The FY2029 and FY2030 rows are excluded from every conclusion, and the FY2028 row is used only as a cross-check with its three-analyst coverage disclosed.

est.ebitdaAvg and est.ebitAvg are the most extreme fixed-ratio fabrications in this batch — REJECTED. ebitdaAvg is exactly 80.81% of revenueAvg in every year from FY2023 to FY2030; ebitAvg is exactly 79.67%. An 80.8% EBITDA margin is not a plausible figure for any company; Altria's actual fiscal 2025 EBITDA margin was 53.8%. The vendor's FY2026 ebitdaAvg of $16,600M overstates a realistic figure by roughly 50%. These rows are unusable and are not touched.

est.epsAvg is on an adjusted basis and validates reasonably. The FY2025 row of $5.434 sits close to the sum of reported adjusted quarters. All forward valuation runs on epsAvg.

Peer context. The vendor peer set is a reasonable consumer-defensive cohort with three genuine tobacco comparables — British American Tobacco (BTI), Turning Point Brands (TPB), Universal Corp (UVV) and 22nd Century (XXII) — alongside Anheuser-Busch InBev, Colgate, Diageo, Mondelez, Monster and Target. Notably absent: Philip Morris International, the closest comparable and the subject of all three of the knowledge base's entity-level claims. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.

4a. What today's price assumes (the inversion)

At $68.07 — 11.6x FY2027 consensus with a 6.23% dividend — the price embeds:

• Adjusted EPS reaches $5.87 in 2027 and $6.10 in 2028 — +3.5% then +3.9% (consensus; 8 and only 3 analysts) — on revenue growth of 0.8% and 1.1%. The price is not assuming growth; it is assuming stability.
• Net price realisation continues to exceed volume decline. (Our number, derived from the filing.) The June quarter converted a 4.5% volume decline into 0.7% revenue growth net of excise — roughly 5.2 points of price and mix against 4.5 points of volume. This is the most fragile assumption in the price, and the reason is the discount share: at 33.8% and rising 2.6 points a year, the consumer's tolerance for the annual increase is visibly narrowing.
• The dividend is maintained and raised. (Our number; the current payout is 76.7% of free cash flow.) At a constant $4.24 the market is paying 16.1x the dividend. At a 7% required yield the stock is $60.57; at 6% it is $70.67; at 5.5% it is $77.09. The valuation is a yield decision, not an earnings decision.
• Regulatory conditions do not deteriorate discontinuously. (Our assumption.) Menthol, nicotine-level and excise-tax actions are all live and none is in the estimates.
• Nothing pharmacological reduces nicotine demand. (Our number, prompted by the knowledge base.) Two claims — half-weighted as conflicted management voice — state that GLP-1 medicines reduce craving cycles and that scaled studies in nicotine addiction were beginning.

4b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: EPS growth (+3.9%, from FY2027E $5.874 to FY2028E $6.102) + multiple drift (HOLD, at roughly 11.6x, 0%) + shareholder yield (+6.83%, being a 6.23% dividend and roughly 0.6% of net buyback) ≈ +10% to +11%.

This is the only name in this batch where the shareholder yield is the largest component of the expected return, and it is a genuinely different kind of bridge. We assume the multiple HOLDS rather than expands or compresses, and the reason is that at 11.6x forward earnings and a 6.23% yield, Altria is priced as a bond substitute rather than as an equity — the multiple has been in a 9-14x band for years and moves with required yield rather than with growth expectations. If the market's required yield on this cash stream falls from 6.23% to 5.5%, the stock is $77; if it rises to 7%, the stock is $61. That, not the earnings, is the variance.

If the multiple simply held and EPS grew 3.9%, the twelve-month total return would be approximately 10.1% — 3.9% price plus 6.23% dividend. That is the whole proposition, and it does not require anything to go right. What it requires is that nothing goes wrong with volume, price, regulation or the payout.

4c. Variant perception (where we differ, what would surprise)

• Our largest divergence is from the DATA, and on this name it is severe. Every screen computing year-on-year revenue growth from inc_q will show Altria growing 15.5% in the June quarter and 20.1% in March. The company grew 0.1% and, for the half, 1.6%. The cause is two different income-statement lines compared across years, and it takes the 10-Q to see it. A momentum or growth screen would currently rank Altria as an accelerating business.
• We do NOT differ from the street on value. Consensus is $72.33; our base is $73. When our number and the crowd's are within a dollar and the knowledge base is empty, there is no edge, and no-edge names default toward Watch.
• We think the discount-share number is under-weighted and it is the one operating datum we would elevate above all others. 33.8% of the cigarette category is now discount, up 2.6 points in twelve months and 0.5 sequentially, and the company attributes it to "discretionary income pressures". Altria's entire model is annual price increases on a premium brand. The rate of trade-down is the leading indicator of when that model stops working, and it is accelerating, not stabilising.
• We flag one long-run risk the market does not price and the knowledge base does raise, with an explicit conflict disclosure. Two claims from the eli_lilly_ceo channel — management voice of a pharmaceutical company whose products would reduce tobacco demand, therefore half-weighted and conflicted — state that GLP-1 medicines reduce craving cycles, that large studies in nicotine addiction were starting, and that there are "early signals" the class reduces the desire for alcohol and cigarettes. A pharmacological reduction in nicotine demand is a different order of threat from a category shift, and no financial statement will warn about it in advance. We do not forecast it; we record it as the one item in this file that could change the terminal value rather than the growth rate.
• Positive surprise: the discount share stabilising or falling; volume decline moderating below 4%; Altria's oral tobacco share stabilising against the pouch category; or a dividend increase above the historical mid-single-digit rate.
• Negative surprise: the discount share rising above 36%; volume decline exceeding 6%; revenues net of excise turning negative; a menthol or nicotine-level regulatory action; or any change to the dividend, which is the entire reason this security is owned.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted-EPS distribution — mean $5.874, low $5.774, high $6.024 (8 analysts) — cross-checked against the implied dividend yield at each level, which for this name is the more meaningful frame.

• Bear ~$58 — 10.0x the FY2027 consensus LOW of $5.774, implying a 7.31% dividend yield at the current $4.24. Cross-check: 6% above the 52-week low of $54.72. The scenario: the discount share pushes through 36%, price realisation stops covering a volume decline that accelerates past 6%, revenues net of excise turn negative, the buyback is suspended to protect the dividend, and the market demands a distressed yield. −14.8%.
• Base ~$73 — 12.4x the FY2027 consensus MEAN of $5.874, implying a 5.81% dividend yield. Cross-check: 11.9x FY2028E; a 6.9% free-cash-flow yield; 2.6% below the 52-week high. Sensitivity, stated openly: an 11x multiple gives $65 and a 14x gives $82 — and the equivalent yield frame is 6.5% gives $65, 5.5% gives $77. The whole answer lives in a 5.5-6.5% required-yield band. The scenario: price continues to outrun volume by a narrow margin, EPS compounds 3-4%, the dividend is raised at the historical rate, and the required yield stays where it is. +7.2%, plus the 6.23% dividend.
• Bull ~$90 — 14.9x the FY2027 consensus HIGH of $6.024, implying a 4.71% dividend yield. Cross-check: 20% above the 52-week high of $74.92 and 13.9% above the street's high target of $79. The scenario: interest rates fall materially and income substitutes re-rate; the nicotine-pouch counter-thesis holds that total nicotine demand grows rather than shrinks and Altria participates; enforcement against illicit vapes continues to moderate cigarette volume decline; and the market pays a staples multiple for a 45% free-cash-flow margin. +32.2%.

Base is 7.2% above spot and, including the 6.23% dividend, implies a roughly 13.4% total return to fair value. Asymmetry is 2.18:1 to the upside on price alone (14.8% down, 32.2% up). What holds this at Watch is that our base is within a dollar of the street's, the conviction lane is empty, and the one operating metric that decides the thesis — the discount share — is moving the wrong way at an accelerating rate.

5. Knowledge base — empty on the name, precise on the model

Raw entity hits naming Altria: ZERO. Case-sensitive entity sweep on the ticker "MO": ZERO. Competitor entity hits (Philip Morris): 3. Sector text sweep: 14 hits, roughly 7 usable, 2 of them half-weighted.

The primary sweep covered a case-sensitive standalone MO — a string that collides with the state of Missouri, month abbreviations and ordinary words — plus entity matches on Altria, Philip Morris, Marlboro and NJOY. The case-sensitive ticker sweep returned nothing at all, which is the cleanest possible result for a collision-prone string and is recorded as such.

Three claims name Philip Morris International — a different company — and are competitor context, not name-level conviction. One of them matters:

> 2024-10-14 · bullish · conviction 70 · entities: Zyn, Philip Morris, PM · channel: business_breakdowns

> "Zyn's US stranglehold shows modern-oral brands, once established, are very hard to displace — strong loyalty plus PM's distribution fueled its growth."

Read that against the 10-Q's disclosure that the US nicotine pouch category grew 8.1 share points to 59.9% of oral tobacco while Altria's Smokeless revenue grew 0.9%, and the two corroborate from opposite sides. The knowledge base's assessment of the competitor is the explanation for Altria's segment result.

The usable sector claims, all from one business_breakdowns tobacco episode dated 2024-10-14 unless noted:

> conviction 85 · principle: "Advertising bans and declining users make new cigarette entrants impossible, locking in an oligopoly where incumbents raise prices to offset volume declines."

> conviction 85 · principle: "Tobacco businesses have stable ~40% operating margins, minimal capex, and near-total FCF conversion, funding large dividends and buybacks."

> conviction 75 · principle: "As less-harmful nicotine products proliferate, total nicotine demand may grow rather than shrink — nicotine becomes a caffeine-like widely-used drug."

> conviction 55: "ESG-driven divestment is a fading overhang."

> 2025-04-29 · neutral · conviction 55 · invest_like_the_best: "Tobacco was historically a top-performing stock validating the brand-loyalty insight, but that insight is now largely priced in."

The first two describe Altria's model with unusual accuracy — and Altria beats the stated benchmark, running a 59.8% operating margin against the claim's ~40% and 1.1% capital intensity. The third is the bull case for the category and is directly contradicted by Altria's own results, which show the category growing and Altria not capturing it. The fifth is the honest counterweight and is neutral rather than bearish.

The bearish claims, and a conflict disclosure.

> 2024-10-14 · BEARISH · conviction 50 · channel: eli_lilly_ceo

> "US cigarette consumption in structural decline — sales down 26% since 2019 — enough to pressure convenience-store traffic."

> 2025-01-09 · bullish (on Lilly) · conviction 60 · channel: eli_lilly_ceo

> "GLP-1 medicines reduce craving cycles; large studies starting next year in alcohol, nicotine and drug abuse open new indications beyond weight."

> 2025-03-26 · conviction 60 and 45 · channel: eli_lilly_ceo

> "Early signals GLP-1 class reduces alcohol/cigarette desire via hedonistic centers; Lilly running scaled studies to prove it."

Conflict disclosure, stated plainly. These come from a pharmaceutical company's own channel and are, in substance, management voice describing a product that would reduce demand for the category Altria sells. Under the house rule they are half-weighted and excluded from any conviction pool, and they are quoted here because the risk they describe is real, is not priced anywhere, and appears nowhere in Altria's filings. Note also the caution warranted about this channel generally: in the Starbucks dive in this same batch, nine claims filed under eli_lilly_ceo turned out to be a misattributed Starbucks management interview. The GLP-1 content here is consistent with the channel's nominal identity, but the channel's attribution reliability is demonstrably imperfect and that is disclosed.

Discards: the 'tobacco moment' used as a litigation metaphor for social media (a genuine homograph — the claim is about Meta, not tobacco); two huberman_lab neuroscience claims about nicotine's dopamine response and placebo dose-response, which have no market content; and two invest_like_the_best claims about secondary reinforcers as a general branding principle.

Conclusion. Conviction: NONE at the name level. Breadth 3. Claim count naming Altria: ZERO. The lane's value is that it describes the oligopoly model with precision, identifies the competitor winning the growth category, and raises one long-run pharmacological risk — from a conflicted source — that nothing else in this file would surface.

6. Data integrity — what we rejected and why

Eight findings.

1. inc_q MIXES TWO REPORTING BASES ACROSS YEARS — the growth rate is unrecognisable. The 2026 quarters ($6,111M and $5,428M) are net revenues, gross of excise tax, and match the 10-Q exactly; the 2025 quarters ($5,290M and $4,519M) are on the revenues-net-of-excise basis. A year-on-year calculation from inc_q gives +15.5% for the June quarter; the 10-Q's like-for-like figures are +0.1% (net revenues) and +0.7% (net of excise). This is the APP failure mode and it is the most consequential finding on this name. All growth rates in this dive come from the 10-Q.

2. earn_cal.revenueActual reports an IDENTICAL $5,356M for two consecutive quarters and matches no basis — DISCARDED. Both the 2026-04-30 and 2026-07-30 rows read $5,356M. The 10-Q's figures are $5,428M/$4,758M (Q1) and $6,111M/$5,392M (Q2) on the two bases. Against a Q1 estimate of $4,577.5M this manufactures a 17.0% revenue beat that did not occur. earn_cal revenue is discarded entirely; the EPS rows are used and have a consistent adjusted basis.

3. seg_prod and inc_a are on DIFFERENT revenue bases — both used, labelled. seg_prod sums to $23,292M for fiscal 2025 (net revenues, gross of excise); inc_a reports $20,139M (net of excise). The $3,153M difference is excise tax. No reconciliation is supplied in the payload and none is flagged.

4. est.ebitdaAvg and est.ebitAvg are the most extreme fixed-ratio fabrications in this batch — REJECTED. ebitdaAvg is exactly 80.81% of revenueAvg and ebitAvg exactly 79.67% in every year FY2023 to FY2030. An 80.8% EBITDA margin is not a plausible figure for any company. Altria's actual fiscal 2025 EBITDA margin was 53.8%, so the vendor overstates by roughly 50%. The fabrication is almost certainly the net-revenues-versus-net-of-excise confusion applied to a margin — but whatever its origin, the rows are unusable.

5. Estimate coverage is thin and collapses after FY2027. 7-8 analysts on FY2026 and FY2027 EPS, only 3 on FY2028, and ONE on each of FY2029 and FY2030 — against 26 analysts in the grades block. The FY2029 and FY2030 rows are excluded from every conclusion.

6. Fiscal 2024 GAAP earnings are anomalous and must not be used as a base. Net income of $11,264M and EPS of $6.54 against fiscal 2025's $6,947M and $4.11. Pre-tax income was $13,658M against $9,389M, EBITDA $15,068M against $10,832M, and cf_a shows acquisitionsNet of +$2,353M — a large disposal gain. Any growth rate computed from fiscal 2024 GAAP earnings is meaningless, and the fiscal 2025 "decline" of 38% is an artefact.

7. Book-equity metrics are meaningless — REJECTED as lenses. priceToBookRatioTTM (−42.66x), debtToEquityRatioTTM (−9.21x), bookValuePerShareTTM (−$1.57) and returnOnEquityTTM (null in ratios_ttm) are artefacts of shareholders' equity of −$3,502M against retained earnings of PLUS $35,452M — decades of buybacks, not losses. returnOnInvestedCapitalTTM of 36.7% is used instead.

8. dividendPayoutRatioTTM of 85.6% is computed on GAAP earnings and overstates the strain — corrected on cash. Fiscal 2025 dividends of $6,960M against free cash flow of $9,074M is 76.7%, with $2.1 billion of annual headroom. The GAAP figure is arithmetically correct and economically misleading for a company whose GAAP earnings are depressed by non-cash amortisation on $17.7 billion of intangibles.

Not defects, correctly reported and independently confirmed: seg_geo is EMPTY and correctly so — Altria operates only in the United States, the same legitimate case as Progressive in this batch; inc_q June-quarter net revenues of $6,111M match the 10-Q exactly, as does the derived Q1 figure of $5,428M; profile.ceo reads "Sal Mancuso", which is current — the 8-K of 2026-05-18 confirms his election effective 14 May 2026, so this is a rare case of the profile block being FRESH rather than stale, and it is recorded as a positive finding; capexToRevenueTTM is consistent with $216M on $20,139M; interestCoverageRatioTTM of 10.3x is consistent with the debt load; profile.currency and inc_a[0].reportedCurrency are both USD — no currency mixing; and earn_cal EPS uses a consistent adjusted basis across all five reported rows, so the surprise series (+3.6%, +0.7%, −1.5%, +6.5%, −1.3%) is like-for-like.

8-K scan — completed, with a governance finding. The three retained 8-Ks are 2026-04-30 (Q1 results, cover only), 2026-05-18 (Item 5.02 — the chief executive and chief financial officer transition) and 2026-07-30 (Q2 results, cover only). The 2026-05-18 filing documents that William F. Gifford Jr. retired as chief executive effective 14 May 2026 and that Salvatore Mancuso was elected in his place, with Gifford serving as a consultant through 31 December 2026 at $250,000 per month and forfeiting all unvested restricted and performance stock units granted in 2024 and 2025. No merger, acquisition, divestiture or capital-structure event postdating the 30 June 2026 balance sheet appears. Verified clean on corporate actions; the governance change is disclosed.

Non-equity tripwire — checked and passed. MO is common stock, NYSE-listed. The check was warranted here: beta of 0.494 and a 6.23% dividend yield are both fixed-income-like characteristics. But the dividend is variable and has been raised annually for decades rather than fixed; the price of $68.07 is not par-like ($25 or $1,000); volume was 9.92M shares (~$675M of turnover); and the 52-week band of $54.72 to $74.92 is a 37% range, far wider than a fixed-income instrument. This is common equity, and the bond-like characteristics are genuine properties of the business rather than instrument artefacts.

7. Technicals

• Price $68.07, down 0.28%. −9.1% from the 52-week high of $74.92; +24.4% above the low of $54.72. Position within the annual range: 66.2nd percentile.
• Moving averages, split: −4.9% below a 50-day of $71.59, which is falling; +3.8% above a 200-day of $65.60, which is rising. The intermediate trend is down; the long-term trend is up.
• RSI 43.0 — weak. MACD −0.66 — negative.
• Beta 0.494 — the second lowest in this batch after Progressive's 0.246.
• Relative performance: 3-month −7.3% vs SPY +7.6% — a 15-point gap; 6-month +9.4% vs SPY +11.1%; 12-month +10.2% vs SPY +24.3% and QQQ +30.8%.
• Sentiment: 16 buy, 9 hold, 1 sell across 26 analysts. Consensus $72.33 (+6.3%), median $74 (+8.7%), high $79 (+16.1%), low $64 (−6.0%).

What the technical picture does to the entry. On a 0.494-beta yield instrument the chart is close to irrelevant and the yield is the price. At $68.07 the dividend yields 6.23%; at the 52-week high it yielded 5.66%; at the low, 7.75%. The useful framing is: a buyer today accepts a 6.23% starting yield on a cash stream growing 3-4% a year, from a company whose unit volumes fall 4.5% a year. The 3-month underperformance of 15 points against the S&P has improved that starting yield, and the falling 50-day suggests it may improve further. There is no urgency and, at a 0.494 beta, no timing edge available.

8. Insiders and governance

The insider block for Altria contains no transactions that support inference in the records available — reported as an absence of data.

The governance change is the meaningful item and it comes from the 8-K of 2026-05-18. William F. Gifford Jr. retired as chief executive effective 14 May 2026 and Salvatore Mancuso — previously chief financial officer — was elected in his place, with a base salary of $1,350,000, a grant of 40,634 restricted stock units and 37,246 performance stock units vesting in 2031, and an annual equity target of $8.5 million. Gifford forfeited all unvested 2024 and 2025 restricted and performance stock units on retirement and will consult to the board through 31 December 2026 at $250,000 per month.

Two observations. First, the vendor's profile.ceo field correctly reads "Sal Mancuso" — which, given that the data contract specifically names stale profile fields as a known defect class (DHR's named chief executive was superseded by an 8-K the day before), is worth recording as a clean result. Second, a chief financial officer promoted to chief executive of a company in managed decline is a continuity appointment, not a strategic reset — and the strategic question this business faces, which is how to win in smoke-free nicotine after losing the pouch category, is precisely the one a continuity appointment is least likely to answer differently.

9. Verdict, kill-criteria and flip conditions

Watch.

What is genuinely excellent: a 59.8% operating margin and a 45.1% free-cash-flow margin; capital expenditure of $216 million on $20.1 billion of revenue — 1.1%, the lowest in this batch; $9,074 million of free cash flow, a 7.98% yield; a 36.7% return on invested capital; a $4.24 dividend yielding 6.23% and covered at 76.7% of free cash flow, with $2.1 billion of annual headroom — the direct opposite of Starbucks in this same batch; net debt at 1.89x EBITDA with 10.3x coverage; beta of 0.494; a share count down 9.8% in five years; and an oligopoly structure that a knowledge-base claim at conviction 85 describes as making new entrants impossible.

What holds us back: cigarette shipment volume down 4.5% with the industry down 5%; the discount share of the cigarette category at 33.8%, up 2.6 points in twelve months and 0.5 sequentially, which the company itself attributes to consumer income pressure and which is the leading indicator of the price lever failing; the US nicotine pouch category at 59.9% of oral tobacco, up 8.1 points, while Altria's own smokeless revenue grew 0.9% — the growth category is being lost to a competitor whose position the knowledge base calls a "stranglehold"; revenue net of excise down in each of the last four years; a base fair value of $73 that is within a dollar of the street's $72.33; zero knowledge-base claims naming this company; and a long-run pharmacological risk — GLP-1 agents reducing nicotine craving — that is unpriced, unmeasurable, and raised only by a conflicted source.

The distinction that matters. This is not a broken company and it is not a value trap in the ordinary sense — the dividend is covered, the leverage is moderate, and the cash generation is close to best-in-class. It is a business whose one operating lever, price, is visibly meeting resistance for the first time in years, and whose one growth adjacency has already been won by someone else. At 11.6x forward earnings with a 6.23% yield, the total-return arithmetic of roughly 10% a year is respectable and requires nothing to go right. It also offers nothing if something goes wrong, and our own number sits on top of the crowd's. Watch.

Pre-registered KILL criteria — what would take this to Avoid:

• The discount retail share of the cigarette category rising above 36%, from 33.8% and rising 2.6 points a year. This is the single number that would confirm the price lever has broken.
• Inventory-adjusted cigarette shipment volume declining more than 6% in any quarter.
• Revenues net of excise taxes turning NEGATIVE year on year, which would mean price no longer covers volume at all.
• Any change to the dividend, which is the entire reason this security exists in a portfolio.
• A menthol ban, nicotine-level mandate or major federal excise increase — the discontinuous regulatory risks that no estimate reflects.
• Credible Phase 3 evidence that a GLP-1 or similar agent materially reduces smoking prevalence at scale, which would change the terminal value rather than the growth rate.

Pre-registered FLIP conditions — what would take this to Buy — Tactical:

• Price below approximately $61 (10.4x FY2027E), where the dividend yields 7.0% and the base case is +19.7% before the dividend. That is 10.4% below today's close and above the 52-week low.
• The discount share stabilising or falling for two consecutive quarters, which would show the annual price increase is again within the consumer's tolerance.
• Altria's oral tobacco share stabilising against the nicotine pouch category, which would mean the growth adjacency is not permanently lost.
• Volume decline moderating below 3.5% on a sustained basis rather than on illicit-vape enforcement, which the 10-Q identifies as the current and reversible cause.
• Any name-level knowledge-base conviction appearing. The lane is completely empty, and for a company this widely followed that absence is itself informative.

Where MO fits in the Synthos Framework Portfolio. The defensive-income sleeve, at 0% today with a 1.5% target on a fill near $61 or a stabilising discount share. Batch overlap note: Progressive (PGR) is the only other low-beta defensive here (beta 0.246 against Altria's 0.494), and the two are opposite propositions — Progressive is a growing-unit cyclical at a cyclical earnings peak with a variable dividend that is really a special; Altria is a declining-unit annuity at trough growth with a genuine, covered 6.23% yield. For an income mandate Altria is the more honest instrument of the two, and this dive says so notwithstanding the Watch. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $68.07.

Single biggest risk: price stops outrunning volume. Altria's model requires net price realisation to exceed a 4.5% annual volume decline, every year, forever. In the June quarter it managed it by roughly 0.7 percentage points — 5.2 points of price and mix against 4.5 points of volume. The margin of victory is narrow and the resistance is measurable: the discount share of the cigarette category is 33.8% and rising 2.6 points a year, which the company attributes in its own words to "discretionary income pressures on adult nicotine consumers" that have "negatively impacted the sales volumes of certain of our operating companies' premium brands." That is Marlboro losing volume to cheaper cigarettes because the price gap has widened past what the consumer will pay. If that trend continues at its current rate, the discount share passes 36% within a year and 40% within three, and at some point in that progression the annual increase stops being collectable. When it does, a 59.8% operating margin, a 7.98% free-cash-flow yield and a 6.23% dividend all reprice at once — and there is no second business to absorb it, because the growth category has already been won by somebody else.

Provenance & disclosures

• Traceability: ZERO tagged knowledge-base claims name Altria (entity sweep on Altria, Marlboro and NJOY returned nothing; a case-sensitive entity sweep on the standalone ticker "MO" — a highly collision-prone string — also returned ZERO, which is the cleanest possible result and is recorded as such). Three entity hits name Philip Morris International, a different company, and are treated as competitor context; one is materially useful — a business_breakdowns claim (2024-10-14, conviction 70) that "Zyn's US stranglehold shows modern-oral brands, once established, are very hard to displace", which explains from the winner's side the 10-Q's disclosure that the nicotine pouch category took 8.1 share points while Altria's smokeless revenue grew 0.9%. A sector sweep on tobacco, cigarette, nicotine, vaping, Marlboro and Altria returned 14 text hits, of which roughly seven are usable: two principle claims at conviction 85 from a 2024-10-14 business_breakdowns tobacco episode that describe the oligopoly model and the cash characteristics with unusual precision; a conviction-75 claim that total nicotine demand may grow as less-harmful products proliferate; a conviction-55 claim that ESG divestment is a fading overhang; an invest_like_the_best claim (2025-04-29, neutral 55) that the brand-loyalty insight is "now largely priced in"; and three bearish claims from the eli_lilly_ceo channel — one on US cigarette consumption being down 26% since 2019, and two on GLP-1 medicines reducing nicotine craving with scaled studies beginning. THOSE THREE ARE MANAGEMENT VOICE OF A PHARMACEUTICAL COMPANY WHOSE PRODUCT WOULD REDUCE DEMAND FOR THE CATEGORY ALTRIA SELLS: they are half-weighted, excluded from any conviction pool, and the conflict is disclosed. A further caution is recorded: in the SBUX dive in this same batch, nine claims filed under eli_lilly_ceo proved to be a misattributed Starbucks management interview, so this channel's attribution reliability is demonstrably imperfect. Discards include a genuine homograph — "social media's tobacco moment" used as a child-addiction-litigation metaphor in a claim about Meta — plus two huberman_lab neuroscience claims on nicotine's dopamine response and placebo dose-response with no market content, and two general branding-principle claims. All quotes are verbatim from the stored claim text.
• Data as-of: most recent filing-verified financials 2026-06-30, from the 10-Q filed 2026-07-30 (income statement on both revenue bases, cigarette shipment volume, discount share, nicotine pouch category share, and the cost commentary) · annual statements fiscal 2025 ended 2025-12-31 from inc_a/bal_a/cf_a, corroborated by the 10-K filed 2026-02-25 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873602 = 2026-08-04T20:00:02Z ($68.07, −0.28%; 50-DMA $71.59; 200-DMA $65.60; RSI 43.0; MACD −0.66; beta 0.494) · knowledge-base claims 2026-08-04. Fiscal note: Altria's fiscal year is the calendar year. CRITICAL BASIS NOTE: Altria reports revenue on two lines — "Net revenues" (gross of excise tax) and "Revenues net of excise taxes" — and the vendor payload uses both without labelling them. All figures come from the Synthos vendor data file for MO or from the SEC filings in the MO archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-25 (fiscal 2025); 10-K filed 2023-02-27 (fiscal 2022 — an unusual second annual report retained in this archive, not used); 10-Q filed 2026-04-30 (March 2026 quarter); 10-Q filed 2026-07-30 (June 2026 quarter, the source of all operating data used here); 8-K filed 2026-04-30 (Q1 results, cover only); 8-K filed 2026-05-18 (Item 5.02 — the chief executive and chief financial officer transition, documenting William Gifford's retirement effective 14 May 2026 and Salvatore Mancuso's election); 8-K filed 2026-07-30 (Q2 results, cover only).
• Where the filings contradicted or corrected the vendor (detailed in Section 6): inc_q MIXES TWO REPORTING BASES ACROSS YEARS — the 2026 quarters are net revenues (gross of excise) and match the 10-Q exactly, while the 2025 quarters are revenues net of excise, producing an apparent +15.5% June-quarter growth rate against a true +0.1%; earn_cal.revenueActual reports an IDENTICAL $5,356M for two consecutive quarters, matching neither basis, and manufactures a 17.0% revenue "beat" in Q1 — discarded entirely; seg_prod identified as being on the net-revenues basis while inc_a is net of excise, a $3,153M difference with no reconciliation supplied; est.ebitdaAvg and est.ebitAvg rejected as the most extreme fixed-ratio fabrications in this batch — exactly 80.81% and 79.67% of revenue in every year, against an actual fiscal 2025 EBITDA margin of 53.8%; fiscal 2024 GAAP earnings identified as containing a large disposal gain (acquisitionsNet +$2,353M) and excluded as a base; book-equity metrics rejected as artefacts of buybacks against positive retained earnings of $35,452M; dividendPayoutRatioTTM of 85.6% corrected to 76.7% on a free-cash-flow basis. Where vendor and filing AGREED — worth recording: inc_q June-quarter net revenues of $6,111M match the 10-Q to the dollar; seg_geo is correctly EMPTY because Altria operates only in the United States; and profile.ceo reads "Sal Mancuso", which the 8-K of 2026-05-18 confirms as CURRENT — a clean result on a field the data contract specifically names as a known stale-data risk. The 8-K scan returned no corporate action postdating the 30 June 2026 balance sheet.
• Basis note: analyst estimates and earn_cal EPS actuals are adjusted (non-GAAP); reported diluted EPS is GAAP. Trailing adjusted EPS is $5.55 against trailing GAAP diluted of $4.769, a 16.4% gap driven principally by amortisation on $17.7 billion of intangibles and by asset-impairment and restructuring items. The earn_cal EPS basis is consistent across all five reported rows, so the surprise series (+3.6%, +0.7%, −1.5%, +6.5%, −1.3%) is like-for-like and shows a well-guided company with small deviations in both directions. The earn_cal REVENUE series is not usable and is discarded. Forward multiples use consensus adjusted EPS; the trailing multiple is shown on both bases (12.26x adjusted, 14.27x GAAP diluted).
• Estimate coverage: only 7-8 analysts on FY2026 and FY2027 EPS, 3 on FY2028, and ONE on each of FY2029 and FY2030 — against 26 analysts in the grades block. The FY2029 and FY2030 rows are excluded from every conclusion; the FY2028 row is used only as a cross-check with its three-analyst coverage disclosed. The fair-value anchors rest on the FY2027 row (8 analysts), and the dispersion there is unusually tight (low $5.774, mean $5.874, high $6.024 — a 4.3% spread), which is what a highly predictable business looks like.
• Peer note: the vendor peer set contains three genuine tobacco comparables — British American Tobacco, Turning Point Brands, Universal Corp and the micro-cap 22nd Century — alongside Anheuser-Busch InBev, Colgate, Diageo, Mondelez, Monster and Target. Philip Morris International, the closest comparable and the subject of all three of the knowledge base's entity-level claims, is ABSENT. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.
• Fair-value caveat: the $58 / $73 / $90 anchors are multiples of the FY2027 consensus adjusted-EPS distribution — 10.0x the low of $5.774, 12.4x the mean of $5.874, and 14.9x the high of $6.024 — and are cross-checked against the implied dividend yield at each level (7.31%, 5.81% and 4.71% on the current $4.24), which for a security priced as an income instrument is the more meaningful frame. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed both ways: an 11x multiple gives $65 and a 14x gives $82; a 6.5% required yield gives $65 and a 5.5% gives $77. Section 4b states plainly that the base assumes the multiple HOLDS, and that for this name the variance is the market's required yield rather than the earnings.
• Timing: second-quarter results were released 2026-07-30, five days before this dive, so the first half is in the data. The next print is 2026-10-29, 86 days away — there is no near-term company-specific catalyst, which is an explicit input to the Watch verdict. 2026-08-04 was a marginally negative day for the stock (−0.28%) in a broadly higher market; no company-specific news for that date appears in this file.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.